有关早期胃癌诊断的研究进展
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v4i4.5453
Abstract
在全球范围内,胃癌是最为常见的恶性肿瘤之一,严重威胁人类健康问题。根据2018年有关报告显示,全球胃癌新发病例1,033,701,发病率排名第5,而死亡782,685例,死亡率排名第3[1]。随着经济发展、生活条件改善以及根除幽门螺杆菌治疗等预防措施的进步,在全球范围内,尤其是西欧、北美等发达国家呈下降趋势[2,3],但在东亚、东欧、拉丁美洲等地区胃癌的防治形势依然严峻。我国近年来胃癌的发病率呈下降趋势,但死亡率下降趋势并不明显,导致死亡率下降趋势并不明显的原因之一为大部分患者错失早期胃癌的诊断时机,疾病已经发展到中晚期。在我国消化系统恶性肿瘤中,胃癌发病率最高,一项研究表明在我国农村地区胃癌发病率几乎是城市地区的二倍[4]。由于早期胃癌无明显的临床表现、筛查机制不完善等种种原因,大部分患者在出现明显的身体不适时就诊,导致错过早期胃癌的诊断机会。手术切除是临床实际工作中最为常用的治疗手段,确诊为早期胃癌根据患者病情制定手术方案,患者治疗效果及预后较好。因此,提高早期胃癌的确诊率做到早发现、早治疗,提高患者生存率。
Keywords
胃癌；Hp；肿瘤标记物；HER-2；早期诊断
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤,2018,27(01):1-14.
[2] Chen W, Zheng R, Baade PD,et al. Cancer statistics in China, 2015.CACancer J Clin.2016;66:115–132.
[3] 石远凯,孙燕.临床肿瘤内科手册[M].第6版.北京:人民卫生出版社,2015.
[4] Park H,Uronis H,Kang YK,et al. Determinants of re⁃sponse of HER2+gastric cancer(GC)vs gastroesophagealjuncti on adenocarcinoma(GEJ)to margetuximab(M)pluspembrolizumab (P)post trastuzumab(T)[J].Ann Oncol,2019,30(9):485.
[5] KIM N.Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism[J].J Gastroenterol Hepatol,2019,34(8):1287-1295.
[6] GUO J X,TAO Q S,LOU P R,et al.miR- 181b as a potential molecular target for anticancer therapy of gastric neoplas ms[J].Asian Pac J Cancer Prev,2012,13(5):2263-2267.
[7] Tian XY,Zhu H,Zhao J,et al.Diagnostic performance of urea breath test,rapid urea test,and histology for Helicobact er pylori infection in patients with partial gastrectomy:a meta-analysis[J].Clin Gastroenterol.2012,46(4):285-292．
[8] Ghaderi Bayazid,Moghbel Hamoon,Daneshkhah Nasrin,et al. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading[J]. Journal of gastrointestinal cancer,2019,50(3):525-529.
[9] Spindler Blake A,Bergquist John R,Thiels Cornelius A,et al. Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer.[J]. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,2017,21(5):770-777.
[10] Jolanda Stiksma,Diana C. Grootendorst,Peter Willem G. van der Linden. CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer[J].Clinical Colorectal Cancer,2014, 13(4):239-244.
[11] Lee Jai Hyuen. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.[J]. Clinical laboratory,2019,65(10).
[12] Wa Zhong, Zhong Yu, Jun Zhan,et al.Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer.[J].Pathology & Oncology Research,2015,21(1):83-95.
[13] Neves Filho EHC,Pires APB,de Sant'Ana RO,et al.The as-sociation among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma[J].Apmis, 2018,126(5):389-395.
[14] 《胃癌HER检测指南》编写组.胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557.
[15] 王昆宇.1363例胃癌 HER-2/neu表达临床流行病学研究[D].吉林大学,2013.
[2] Chen W, Zheng R, Baade PD,et al. Cancer statistics in China, 2015.CACancer J Clin.2016;66:115–132.
[3] 石远凯,孙燕.临床肿瘤内科手册[M].第6版.北京:人民卫生出版社,2015.
[4] Park H,Uronis H,Kang YK,et al. Determinants of re⁃sponse of HER2+gastric cancer(GC)vs gastroesophagealjuncti on adenocarcinoma(GEJ)to margetuximab(M)pluspembrolizumab (P)post trastuzumab(T)[J].Ann Oncol,2019,30(9):485.
[5] KIM N.Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism[J].J Gastroenterol Hepatol,2019,34(8):1287-1295.
[6] GUO J X,TAO Q S,LOU P R,et al.miR- 181b as a potential molecular target for anticancer therapy of gastric neoplas ms[J].Asian Pac J Cancer Prev,2012,13(5):2263-2267.
[7] Tian XY,Zhu H,Zhao J,et al.Diagnostic performance of urea breath test,rapid urea test,and histology for Helicobact er pylori infection in patients with partial gastrectomy:a meta-analysis[J].Clin Gastroenterol.2012,46(4):285-292．
[8] Ghaderi Bayazid,Moghbel Hamoon,Daneshkhah Nasrin,et al. Clinical Evaluation of Serum Tumor Markers in the Diagnosis of Gastric Adenocarcinoma Staging and Grading[J]. Journal of gastrointestinal cancer,2019,50(3):525-529.
[9] Spindler Blake A,Bergquist John R,Thiels Cornelius A,et al. Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer.[J]. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,2017,21(5):770-777.
[10] Jolanda Stiksma,Diana C. Grootendorst,Peter Willem G. van der Linden. CA 19-9 As a Marker in Addition to CEA to Monitor Colorectal Cancer[J].Clinical Colorectal Cancer,2014, 13(4):239-244.
[11] Lee Jai Hyuen. The Feasibility of Serum Multiple Tumor Markers Test Between Patients with Primary Pancreatic Cancer and Those with Benign Pancreatic Cystic Disease.[J]. Clinical laboratory,2019,65(10).
[12] Wa Zhong, Zhong Yu, Jun Zhan,et al.Association of Serum Levels of CEA, CA199, CA125, CYFRA21-1 and CA72-4 and Disease Characteristics in Colorectal Cancer.[J].Pathology & Oncology Research,2015,21(1):83-95.
[13] Neves Filho EHC,Pires APB,de Sant'Ana RO,et al.The as-sociation among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma[J].Apmis, 2018,126(5):389-395.
[14] 《胃癌HER检测指南》编写组.胃癌HER2检测指南[J].中华病理学杂志,2011,40(8):553-557.
[15] 王昆宇.1363例胃癌 HER-2/neu表达临床流行病学研究[D].吉林大学,2013.
Copyright © 2022 孙福田, 吴贵恺
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License